U.S. Selected Practice Recommendations for Contraceptive Use, 2024.

IF 33.7 1区医学 Q1 Medicine

Mmwr Recommendations and Reports Pub Date : 2024-08-08 DOI:10.15585/mmwr.rr7303a1

Kathryn M Curtis, Antoinette T Nguyen, Naomi K Tepper, Lauren B Zapata, Emily M Snyder, Kendra Hatfield-Timajchy, Katherine Kortsmit, Megan A Cohen, Maura K Whiteman

{"title":"U.S. Selected Practice Recommendations for Contraceptive Use, 2024.","authors":"Kathryn M Curtis, Antoinette T Nguyen, Naomi K Tepper, Lauren B Zapata, Emily M Snyder, Kendra Hatfield-Timajchy, Katherine Kortsmit, Megan A Cohen, Maura K Whiteman","doi":"10.15585/mmwr.rr7303a1","DOIUrl":null,"url":null,"abstract":"<p><p>The 2024 U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR) addresses a selected group of common, yet sometimes complex, issues regarding initiation and use of specific contraceptive methods. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25-27, 2023. The information in this report replaces the 2016 U.S. SPR (CDC. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR 2016;65[No. RR-4]:1-66). Notable updates include 1) updated recommendations for provision of medications for intrauterine device placement, 2) updated recommendations for bleeding irregularities during implant use, 3) new recommendations for testosterone use and risk for pregnancy, and 4) new recommendations for self-administration of injectable contraception. The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.</p>","PeriodicalId":51328,"journal":{"name":"Mmwr Recommendations and Reports","volume":"73 3","pages":"1-77"},"PeriodicalIF":33.7000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340200/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mmwr Recommendations and Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.rr7303a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The 2024 U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR) addresses a selected group of common, yet sometimes complex, issues regarding initiation and use of specific contraceptive methods. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25-27, 2023. The information in this report replaces the 2016 U.S. SPR (CDC. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR 2016;65[No. RR-4]:1-66). Notable updates include 1) updated recommendations for provision of medications for intrauterine device placement, 2) updated recommendations for bleeding irregularities during implant use, 3) new recommendations for testosterone use and risk for pregnancy, and 4) new recommendations for self-administration of injectable contraception. The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.

查看原文本刊更多论文

2024 年美国避孕药具使用实践建议选编》。

2024 年美国避孕药具使用实践建议选编》（U.S. SPR）针对特定避孕方法的启动和使用方面的一组常见但有时复杂的问题进行了精选。2023 年 1 月 25 日至 27 日，美国疾病预防控制中心在佐治亚州亚特兰大市对科学证据进行了审查，并与国内专家举行了会议，之后对这些针对医疗保健提供者的建议进行了更新。本报告中的信息取代了 2016 年的美国 SPR（CDC.2016 年美国避孕药具使用实践建议选编》。MMWR 2016;65[No.RR-4]:1-66）。值得注意的更新包括：1）提供宫内节育器放置药物的更新建议；2）植入物使用期间出血不规则的更新建议；3）睾酮使用和妊娠风险的新建议；4）自行注射避孕的新建议。本报告中的建议旨在为医护人员提供循证临床实践指导。这些建议的目的是消除获取和使用避孕药具的不必要医疗障碍，并支持以非胁迫方式提供以人为本的避孕咨询和服务。医疗服务提供者应始终考虑每位寻求避孕服务者的个人临床情况。本报告无意取代针对个别患者的专业医疗建议；必要时，患者应就避孕药具的使用向其医疗服务提供者寻求建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mmwr Recommendations and Reports PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

36.00

自引率

0.00%

发文量

期刊介绍： The MMWR series of publications is published by the Office of Science, Centers for Disease Control and Prevention (CDC), U.S. The MMWR Recommendations and Reports contain in-depth articles that relay policy statements for prevention and treatment in all areas in the CDC’s scope of responsibility (e.g., recommendations from the Advisory Committee on Immunization Practices).